Prevalence and Antifungal Susceptibility of 442Candida Isolates from Blood and Other Normally Sterile Sites: Results of a 2-Year (1996 to 1998) Multicenter Surveillance Study in Quebec, Canada

ABSTRACT During a 2-year surveillance program (1996 to 1998) in Quebec, Canada, 442 strains of Candida species were isolated from 415 patients in 51 hospitals. The distribution of species was as follows: Candida albicans, 54%; C. glabrata, 15%; C. parapsilosis, 12%; C. tropicalis, 9%; C. lusitaniae, 3%; C. krusei, 3%; and Candida spp., 3%. These data, compared to those of a 1985 survey, indicate variations in species distribution, with the proportions of C. glabrata andC. parapsilosis increasing by 9 and 4%, respectively, and those of C. albicans and C. tropicalis decreasing by 10 and 7%, respectively. However, these differences are statistically significant for C. glabrata and C. tropicalis only. MICs of amphotericin B were ≥4 μg/ml for 3% of isolates, all of which were non-C. albicans species. Three percent of C. albicans isolates were resistant to flucytosine (≥32 μg/ml). Resistance to itraconazole (≥1 μg/ml) and fluconazole (≥64 μg/ml) was observed, respectively, in 1 and 1% of C. albicans, 14 and 9% of C. glabrata, 5 and 0% of C. tropicalis, and 0% of C. parapsilosis andC. lusitaniae isolates. Clinical data were obtained for 343 patients. The overall crude mortality rate was 38%, reflecting the multiple serious underlying illnesses found in these patients. Bloodstream infections were documented for 249 patients (73%). Overall, systemic triazoles had been administered to 10% of patients before the onset of candidiasis. The frequency of isolation of non-C. albicans species was significantly higher in this group of patients. Overall, only two C. albicans isolates were found to be resistant to fluconazole. These were obtained from an AIDS patient and a leukemia patient, both of whom had a history of previous exposure to fluconazole. At present, it appears that resistance to fluconazole in Quebec is rare and is restricted to patients with prior prolonged azole treatment.

[1]  P. Wayne.  Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved standard-second edition , 2002 .

[2]  G. St-Germain.  Impact of endpoint definition on the outcome of antifungal susceptibility tests with Candida species: 24‐ versus 48‐h incubation and 50 versus 80% reduction in growth , 2001, Mycoses.

[3]  Ronald N. Jones,et al.  Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998 , 2000, Antimicrobial Agents and Chemotherapy.

[4]  R. Pinner,et al.  The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Salomão,et al.  High rate of non-albicans candidemia in Brazilian tertiary care hospitals. , 1999, Diagnostic microbiology and infectious disease.

[6]  J. Meis,et al.  Nosocomial fungal infections: candidemia. , 1999, Diagnostic microbiology and infectious disease.

[7]  M. Brandt,et al.  Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. , 1999, Diagnostic microbiology and infectious disease.

[8]  L. Nicolle,et al.  Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[9]  M. H. Nguyen,et al.  Influence of Incubation Time, Inoculum Size, and Glucose Concentrations on Spectrophotometric Endpoint Determinations for Amphotericin B, Fluconazole, and Itraconazole , 1999, Journal of Clinical Microbiology.

[10]  J. Sobel,et al.  Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison toC. albicans , 1999, Clinical Microbiology Reviews.

[11]  M. Steinbakk,et al.  Constant Low Rate of Fungemia in Norway, 1991 to 1996 , 1998, Journal of Clinical Microbiology.

[12]  M. A. Martin,et al.  National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. , 1998, Diagnostic microbiology and infectious disease.

[13]  D. Snydman,et al.  Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. , 1998, The Journal of infectious diseases.

[14]  E. Anaissie,et al.  Optimizing the Correlation between Results of Testing In Vitro and Therapeutic Outcome In Vivo for Fluconazole by Testing Critical Isolates in a Murine Model of Invasive Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.

[15]  S. Redding,et al.  Interpretation of Trailing Endpoints in Antifungal Susceptibility Testing by the National Committee for Clinical Laboratory Standards Method , 1998, Journal of Clinical Microbiology.

[16]  T. Sterling,et al.  Resistance to amphotericin B: emerging clinical and microbiological patterns. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[17]  M. Ghannoum,et al.  International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  E. Anaissie,et al.  The epidemiology of hematogenous candidiasis caused by different Candida species. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  L. Peterson,et al.  Effects of incubation time and buffer concentration on in vitro activities of antifungal agents against Candida albicans , 1997, Journal of clinical microbiology.

[20]  D. Snydman,et al.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.

[21]  D. Snydman,et al.  Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. , 1995, Archives of internal medicine.

[22]  J. Serody,et al.  Intravascular Catheter Exchange and Duration of Candidemia , 1995 .

[23]  W. Jarvis.  Epidemiology of nosocomial fungal infections, with emphasis on Candida species. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Pfaller,et al.  Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870 , 1995, Journal of clinical microbiology.

[25]  E. Anaissie,et al.  Detection of amphotericin B-resistant Candida isolates in a broth-based system , 1995, Antimicrobial agents and chemotherapy.

[26]  J. Rex,et al.  Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.

[27]  J. Pottage,et al.  Candida krusei fungemia. Report of 4 cases and review of the literature. , 1993, Medicine.

[28]  G. St-Germain.  Etude de 100 souches de levures isolées de spécimens cliniques normalement stériles , 1988 .

[29]  T. Hadfield,et al.  Mycoses caused by Candida lusitaniae. , 1987, Reviews of infectious diseases.

[30]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.